[Risk on bias assessment: (2) Revised Cochrane risk of bias tool for individually randomized, parallel group trials (RoB2.0)]
- PMID: 28910948
- DOI: 10.3760/cma.j.issn.0254-6450.2017.09.028
[Risk on bias assessment: (2) Revised Cochrane risk of bias tool for individually randomized, parallel group trials (RoB2.0)]
Abstract
This paper introduces the revised cochrane risk of bias tool for individually randomized, parallel group trials (RoB2.0), compates RoB2.0 and the previous version (RoB1.0). And illustrates the application of RoB2.0 for a published clinical trial. As a comprehensive tool, RoB2.0 provides more information on the risk of bias for evidence synthesis. RoB2.0 is still under development and it is suggested that the users should follow the updates of the developers in the future.
本文针对平行设计随机对照试验（RCT）Cochrane偏倚评估工具2.0版本（RoB2.0）的主要内容进行介绍，同时对RoB2.0与前一个版本RoB1.0的区别与联系进行阐述，并举例说明RoB2.0的使用方法和注意事项。RoB2.0内容丰富，覆盖全面，为RCT的证据整合与评价提供了更多的偏倚风险信息。RoB2.0仍处于开发与进一步完善中，使用者可持续关注其后续更新与进展。.
Keywords: Parallel design; Randomized controlled trial; Risk of bias; Systematic review; Tool for assessment.
Similar articles
-
[Bias risk assessment: (3) Revised Cochrane bias risk assessment tool for individual randomized, cross-over trials (RoB2.0)].Zhonghua Liu Xing Bing Xue Za Zhi. 2017 Oct 10;38(10):1436-1440. doi: 10.3760/cma.j.issn.0254-6450.2017.10.028. Zhonghua Liu Xing Bing Xue Za Zhi. 2017. PMID: 29060995 Chinese.
-
[Risk related to bias assessment: (4) Revised Cochrane Risk of Bias Tool for cluster-randomized control trials (RoB2.0)].Zhonghua Liu Xing Bing Xue Za Zhi. 2018 Feb 10;39(2):240-244. doi: 10.3760/cma.j.issn.0254-6450.2018.02.020. Zhonghua Liu Xing Bing Xue Za Zhi. 2018. PMID: 29495213 Chinese.
-
Adherence of systematic reviews to Cochrane RoB2 guidance was frequently poor: a meta epidemiological study.J Clin Epidemiol. 2022 Dec;152:47-55. doi: 10.1016/j.jclinepi.2022.09.003. Epub 2022 Sep 23. J Clin Epidemiol. 2022. PMID: 36156301
-
The revised JBI critical appraisal tool for the assessment of risk of bias for quasi-experimental studies.JBI Evid Synth. 2024 Mar 1;22(3):378-388. doi: 10.11124/JBIES-23-00268. JBI Evid Synth. 2024. PMID: 38287725
-
Risk-of-bias assessment using Cochrane's revised tool for randomized trials (RoB 2) was useful but challenging and resource-intensive: observations from a systematic review.J Clin Epidemiol. 2023 Sep;161:39-45. doi: 10.1016/j.jclinepi.2023.06.015. Epub 2023 Jun 24. J Clin Epidemiol. 2023. PMID: 37364620
Cited by
-
Convalescent plasma may not be an effective treatment for severe and critically ill covid-19 patients: A Systematic Review & Meta-Analysis of Randomized Controlled Trials.Heart Lung. 2022 May-Jun;53:51-60. doi: 10.1016/j.hrtlng.2022.01.019. Epub 2022 Feb 1. Heart Lung. 2022. PMID: 35149308 Free PMC article.
-
Efficacy and safety of non-pharmacological therapies for primary insomnia: a network meta-analysis.Front Neurol. 2025 Jul 29;16:1607903. doi: 10.3389/fneur.2025.1607903. eCollection 2025. Front Neurol. 2025. PMID: 40808922 Free PMC article.
-
A systematic review of deep brain stimulation for substance use disorders.Transl Psychiatry. 2024 Sep 6;14(1):361. doi: 10.1038/s41398-024-03060-1. Transl Psychiatry. 2024. PMID: 39237552 Free PMC article.
-
Endovascular thrombectomy for the treatment of large ischemic stroke: a systematic review and meta-analysis of randomized control trials.medRxiv [Preprint]. 2023 Mar 1:2023.02.27.23286534. doi: 10.1101/2023.02.27.23286534. medRxiv. 2023. Update in: Neurosurgery. 2024 Jan 1;94(1):29-37. doi: 10.1227/neu.0000000000002610. PMID: 36909468 Free PMC article. Updated. Preprint.
-
Direct oral anticoagulation versus no therapy or antiplatelet for stroke prevention in patients with atrial fibrillation and history of intracranial hemorrhage: a systematic review and meta-analysis.Front Med (Lausanne). 2025 Apr 25;12:1570809. doi: 10.3389/fmed.2025.1570809. eCollection 2025. Front Med (Lausanne). 2025. PMID: 40351471 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
